GLAUCOMA TREATMENT METHODS
20220054309 · 2022-02-24
Inventors
Cpc classification
A61F2250/0001
HUMAN NECESSITIES
A61F9/00736
HUMAN NECESSITIES
A61F9/0017
HUMAN NECESSITIES
A61F2250/0003
HUMAN NECESSITIES
A61F2250/0067
HUMAN NECESSITIES
A61F9/00781
HUMAN NECESSITIES
International classification
A61F9/00
HUMAN NECESSITIES
Abstract
A method of surgically altering trabecular meshwork of an eye to create a throughput hole on the meshwork without an implant or a permanent stent comprising inserting an applicator into the meshwork, wherein the applicator has a meshwork-contacting element at its tip section to contact the meshwork and provide energy or mechanical force to the contacted trabecular meshwork.
Claims
1. A method of surgically altering trabecular meshwork of an eye to create at least one throughput hole on said meshwork comprising: inserting a meshwork-contacting element of an applicator into said meshwork and contacting said meshwork, wherein said meshwork-contacting element provides energy or mechanical force to the contacted trabecular meshwork, and thereafter removing the applicator from the eye.
2. The method of claim 1, wherein said meshwork-contacting element is located at a tip section of said applicator.
3. The method of claim 1, wherein said energy is heat energy or cryogenic energy.
4. The method of claim 1, wherein said energy is an alternating heat energy and cryogenic energy cycle.
5. The method of claim 1, wherein the applicator further comprises a piercing member.
6. The method of claim 4, wherein the piercing member is a self-trephining member.
7. The method of claim 1, wherein an exterior surface of the meshwork-contacting element is made of metallic material or energy generating material.
8. The method of claim 1, wherein an exterior surface of the meshwork-contacting element is coated with a pharmaceutical active ingredient.
9. The method of claim 1, wherein an exterior surface of the meshwork-contacting element is porous or having perforated openings.
10. The method of claim 1, wherein an exterior surface of the meshwork-contacting element is a coarse surface or having sharp points so that when the meshwork-contacting element is rotated, the meshwork is ablated or cut away to create the throughput hole.
11. The method of claim 1, wherein a procedure for inserting the meshwork-contacting element into said meshwork is via an ab interno procedure.
12. A method of surgically delivering a pharmaceutical ingredient to trabecular meshwork of an eye comprising: inserting a meshwork-contacting element of a hollow applicator into the meshwork and contacting the meshwork, wherein a surface-medicated balloon is inserted through a lumen of the applicator to the meshwork-contacting element, wherein the surface-coated pharmaceutical ingredient or therapeutic drug is released by inflating the balloon outwardly toward the contacted meshwork, and thereafter removing the applicator from the eye.
13. The method of claim 12, wherein the meshwork-contacting element may be equipped with a plurality of small holes or openings for allowing the balloon surface to contact the target meshwork.
14. The method of claim 12, wherein a procedure for inserting the meshwork-contacting element into said meshwork is via an ab interno procedure.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Following the explanation of the inventions, certain embodiments and modifications thereof will be shown within the detailed descriptions in reference to the figures that follow:
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0053] The drawings overall demonstrate a method for treating glaucoma, both open-angled and closed angle, via trabecular bypass surgery. In particular, the meshwork-contacting element of the device is transiently used to bypass the diseased or deficient trabecular meshwork in order to restore or create outflow pathways; and methods therefore are disclosed. After the procedure, no device or stent is left in the eye. The device is also generally known as the applicator or handpiece in the invention.
[0054] While the following descriptions set forth the device's specifics, it is not to be interpreted as the invention's limitations. Variations of the applications and modifications are also encompassed in the general concepts.
[0055] For background information and illustration purposes,
[0056] The anterior chamber 20 of the eye 10 (
[0057] Referring in particular to
[0058] As shown in
[0059] The trabecular meshwork is an area of tissue in the eye located around the base of the cornea, near the ciliary body, and is responsible for draining the aqueous humor from the eye via the anterior chamber (the chamber on the front of the eye covered by the cornea). The tissue is spongy and lined by trabeculocytes; it allows fluid to drain into a set of tubes called Schlemm's canal flowing into the blood system. Since trabecular meshwork is spongy which is fundamentally different from other tissues of the human body, it would not be obvious to one ordinary skilled in the art to think of using or applying an energy source or mechanical force to ablate trabecular meshwork to generate a spacious throughput (or holes) on the meshwork to enhance aqueous outflow from the anterior chamber.
[0060] The meshwork is generally divided up into three parts, with characteristically different ultrastructures: inner uveal meshwork, corneoscleral meshwork, and juxtacanalicular tissue (also known as the cribriform meshwork). The trabecular meshwork is assisted to a small degree in the drainage of aqueous humor by a second outflow pathway, the uveo-scleral pathway (5-10% of outflow occurs this way). The uveo-scleral pathway is increased with the use of glaucoma drugs such as prostaglandins (e.g., Xalatan, Travatan).
[0061] Surgical methods and relates medical devices for treating glaucoma are disclosed. The method of the present invention comprises trabecular bypass surgery, which involves bypassing diseased trabecular meshwork with the use of a sharp piercing member 49 of an applicator 41, followed by a heat/cryogenic method and/or mechanical rotation force. The device/applicator is inserted into the trabecular meshwork by a piercing member that is slidably advanced through the meshwork, optionally with slight rotation of the piercing member. The rotational mechanism can be found in U.S. Pat. No. 6,102,908, herein cited for reference. In one embodiment as shown in
[0062] The meshwork-contacting element 35 is herein defined in this invention as the element on an applicator 41 to initiate or assist creating a hole (or a spacious throughput) on the trabecular meshwork 21. In a preferred embodiment, the rotating member is manually turned in clockwise or counter-clockwise manner to exert a rotational movement of the meshwork-contacting element at the tip section. In one embodiment, certain non-manual mechanism can be established with the rotating member. The applicator is exposed to the anterior chamber of the eye, allowing fluid collection channels at about an exterior surface of the trabecular meshwork or up to the level of aqueous veins, whereas the meshwork-contacting element of the applicator is positioned through the trabecular meshwork intimately. Some embodiments relate to a method of increasing aqueous humor outflow in an eye of a patient to reduce the intraocular pressure (IOP) therein. In one embodiment, the method comprises bypassing diseased or deficient trabecular meshwork at the level of the trabecular meshwork and thereby complementing existing outflow pathways.
[0063]
[0064]
[0065] Referring in particular to
[0066] As best seen in
[0067] Preferably, the entire exposed surface of the element 35 is biocompatible and tissue compatible so that the interaction/irritation between its exterior surface and the surrounding tissue or aqueous is minimized. In modified embodiments, selected portions or surfaces of the element 35 may comprise a biocompatible and/or tissue compatible material, as needed or desired.
[0068] The element 35 of the illustrated embodiment may be demonstrated in a wide variety of manners. In an exemplary embodiment, the element 35 has a length between about 0.5 millimeters (mm) to about over 1 centimeter (cm), depending on where the device is inserted within the meshwork. The outside diameter of the element 35 may range from 10 micrometers (μm) to about 600 micrometers (μm) or more. In other embodiments, the element 35 may be demonstrated in modified manners with efficacy, as required or desired, giving due consideration to the goals of achieving one or more of the benefits and advantages as taught or suggested herein.
[0069] As best seen in
[0070] From
[0071] The piercing member 49 of the applicator 40 is used to make an incision in the trabecular meshwork 21 and create an opening using the element to advantageously allow the fluid to flow through in a one-step procedure. This one-step procedure may include turning on the RF power for 1-2 seconds or more. In some embodiments, the element is rotated briefly or momentarily to assist creating a throughput hole on the altered trabecular meshwork. The applicator 40 is then withdrawn from the eye and the surgery is concluded, without leaving an implant or stent in place.
[0072]
[0073] In
[0074] The external RF current generator means has the capability to supply RF current by controlling the time, power, and temperature through an optional separate closed-loop temperature control means (not shown here), which is well known to those who are familiar with the technology. The patient is connected to the RF generator means through a DIP electrode to form a closed-loop RF current system. Therefore, RF energy is applied and delivered to the targeted tissue region, through the meshwork-contacting element of this invention. The radiofrequency energy current in this invention is preferably within the range of 50 to 2,000 kHz. In one embodiment, by simultaneously applying RF energy to the electrode element (i.e., the meshwork-contacting element 35) and by applying the rotational therapy, the trabecular meshwork tissue can be altered or ablated as desired or described.
[0075] In a particular embodiment, the material for the RF current delivery medium of this invention consists of conductive metals such as platinum, iridium, gold, silver, stainless steel, Nitinol, or an alloy of the conductive metals.
[0076] For the piercing member 49, the sharp tip 37 may be a surgical needle or a sharp embodiment as needed. In some embodiments, at least one pharmaceutical ingredient or bioactive agent may be added to the meshwork-contacting element of the applicator 40 in order for the at least one pharmaceutical ingredient or bioactive agent to contact and stick to the meshwork. The at least one pharmaceutical ingredient or bioactive agent may be sprayed or painted on and mixed with an adhesive or sticky substance in order for it to stay on the meshwork longer. In one embodiment, the outside diameter (OD) of the meshwork-contacting element 35 can be sized 0.1-0.3 mm or bigger.
[0077] In some embodiment, the meshwork-contacting element 35 may provide cryogenic energy, instead of heat energy as described above, to ablate the trabecular meshwork for enhancing the aqueous outflow once a hole or spacious throughput was created via the cryogenic energy. The cryogenic energy can be supplied via, for example, liquid nitrogen or any cryogenic fluid, through the meshwork-contacting element 35 as taught elsewhere. U.S. Pat. No. 10,251,693 to Newell et al, disclosed an ablation assembly including a controller assembly and a cryogenic ablation catheter, entire content of which are included herein by reference.
[0078] In one embodiment, the invention relates to a method of surgically altering trabecular meshwork of an eye to create a throughput hole on the meshwork comprising: (a) inserting a meshwork-contacting element of an applicator into the meshwork; (b) contacting the meshwork, (c) the meshwork-contacting element provides energy or mechanical force to the contacted trabecular meshwork, and (d) thereafter removing the applicator from the eye.
[0079] In some embodiment, the surface of the meshwork-contacting element 35 may be coated with a pharmaceutical ingredient (or therapeutic drug) that can be released once contacting the desired trabecular meshwork site. In another embodiment, the drug can be releasably stored within the meshwork-contacting element 35. Once at the desired trabecular meshwork site, the therapeutic drug is released. In this particular embodiment, the meshwork-contacting element 35 may be porous or equipped with a plurality of small holes or openings (regular or irregular shapes/configurations) for releasing the drug. Drug of the present invention may include, but not limited to, immunosuppressive drugs which can be classified into five groups: glucocorticoids, cytostatics, antibodies, drugs acting on immunophilins, and other drugs. In one embodiment, the meshwork-contacting element 35 can be a balloon or drug-coated balloon such as cited in the cardiovascular balloon catheter field. A balloon catheter is a type of “soft” catheter with an inflatable “balloon” at its tip which is used during a catheterization procedure to enlarge a narrow opening or passage within the body. U.S. Pat. No. 10,314,948 by Michal et al. disclosed “local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumen”, entire contents of which are included herein for reference.
[0080] In one embodiment, the invention relates to a method of surgically delivering a pharmaceutical ingredient to trabecular meshwork of an eye comprising: (a) inserting a meshwork-contacting element of an applicator into the meshwork; wherein the surface of the meshwork-contacting element is coated with a pharmaceutical ingredient (or therapeutic drug) that can be released once contacting the target trabecular meshwork site; (b) contacting the meshwork; and thereafter removing the applicator from the eye. In another embodiment, the drug can be releasably stored within the meshwork-contacting element. Once at the target trabecular meshwork site, the therapeutic drug is released. In this particular embodiment, the meshwork-contacting element may be porous or equipped with a plurality of small holes or openings for releasing the drug,
[0081] From the foregoing description, it should now be appreciated that an ablation apparatus system for the tubular organs, atherosclerosis, and the treatment of vascular tissues, comprising a suitable energy source and/or a rotational pressure therapy has been disclosed. While the invention has been described with reference to a specific embodiment, the description is illustrative of the invention and is not to be construed as limiting the invention. Various modifications and applications may occur to those who are skilled in the art, without departing from the true spirit and scope of the invention, as described by the appended claims. [0082] Eye 10 [0083] Sclera 11 [0084] Cornea 12 [0085] Iris 13 [0086] Pupil 14 [0087] Limbus 15 [0088] Ciliary body 16 [0089] Choroid 17 [0090] Retina 18 [0091] Optic nerve 19 [0092] Anterior chamber 20 [0093] Trabecular meshwork 21 [0094] Schlemm's canal 22 [0095] Aqueous veins 23 [0096] Conjunctive 24 [0097] Chamber angle 25 [0098] Lens 26 [0099] Outer ring of the element 30 [0100] Inner ring of the element 31 [0101] Positive-charged connector 32 [0102] Negative-charged connector 33 [0103] Metallic guide (centering) 34 [0104] Meshwork-contacting element 35 [0105] Lumen 36 [0106] Sharp tip 37 [0107] Cutting-Edge(Bolster) 38a [0108] Stainless steel tube (Heel of Tip) 38 [0109] Applicator 40 [0110] Tip section of applicator 41 [0111] Power button (continue to push for device to stay on) 42 [0112] Light indicator 43 [0113] Rotational button 44 [0114] Electric conductor 45 [0115] RF generator 46 [0116] Interior surface of meshwork 47 [0117] Exterior surface of meshwork 48 [0118] Piercing member of the applicator 49 [0119] Rotatable member 50 [0120] Tubular shaft 51 [0121] Applicator body 52 [0122] Solid surface 55 [0123] Screen-Type surface 56 [0124] Altering-Type surface 57 [0125] Coarse surface 58